HPLC法测定埃索美拉唑镁肠溶微丸胶囊中主药的含量

目的：建立以HPLC法测定埃索美拉唑镁肠溶微丸胶囊中埃索美拉唑镁含量的方法。方法：以Kromasil C18（250 mm×4.6 mm,5μm）为色谱柱,流动相为乙腈-0.1 mol·L-1磷酸盐溶液（用磷酸调节pH=7.6）=35：65,检测波长为280 nm,流速为1.0 ml·min-1,柱温为30℃,进样量是20μl。结果：埃索美拉唑镁在20.18201.80μg·ml-1范围内进样量与峰面积呈良好的线性关系（r=0.999 7）,平均回收率为100.1%,RSD=0.8%。结论：本法简便、准确、专属性强,可用于试制剂的含量测定。     

复方羟丙茶碱去氯羟嗪胶囊中盐酸克伦特罗的含量测定

目的：建立复方羟丙茶碱去氯羟嗪胶囊（舒喘平胶囊）中盐酸克仑特罗含量测定的方法。方法：采用ZORBAX SB-C18 (4.6 mm×250mm，5μm)色谱柱；以甲醇-0.02mol?L-1磷酸二氢钠溶液（用磷酸调节pH至2.5）为流动相，梯度洗脱；流量1.0mL?min-1；检测波长210nm；柱温35℃；进样量20μL。结果：盐酸克伦特罗的浓度在1.7～6.8μg?mL-1范围内与峰面积呈良好线性关系（r=0.999 9），平均回收率为101.9%，其RSD为3.81%（n=9）。结论：所建方法简便、准确，可作为复方羟丙茶碱去氯羟嗪胶囊中盐酸克伦特罗的定量分析方法。     

HPLC法同时测定桂枝茯苓胶囊中丹皮酚、芍药苷和苦杏仁苷的含量

目的：建立HPLC法同时测定桂枝茯苓胶囊中丹皮酚、芍药苷和苦杏仁苷的含量。方法：采用HPLC法测定桂枝茯苓胶囊中丹皮酚、芍药苷和苦杏仁苷的含量。采用C18柱,流动相为甲醇∶水（55∶45）洗脱,流速为1.0ml·min-1,检测波长为274nm,柱温为30℃,进样体积为10μL。结果：线性范围分别为0.198～3.166μg（r=0.9998）、0.195～3.128μg（r=0.9996）、0.197～30158（r=0.9997）。平均加样回收率分别为99.81%（RSD=2.48%）、99.69%（RSD=1.47%）、99.79%（RSD=2.12%）。结论：本研究建立的方法简便,结果稳定可靠,可用于桂枝茯苓胶囊的质量控制。     

HPLC-DAD法测定祛风止痛胶囊中没食子酸的含量

目的：建立一种适用于测定祛风止痛胶囊中没食子酸含量的高效液相色谱法。方法：采用光二极管阵列检测器（DAD）;固定相为Alttima C18色谱柱（250mm×4.6mm,5μm）;流动相为甲醇-0.2%磷酸溶液（5:95）;检测波长266nm;流量为1.0mL?min-1。结果：没食子酸在0.0666～1.3314μg?ml-1的浓度范围内线性关系良好（r = 0.9999）;平均回收率为100.4%,其RSD为0.74%（n = 6）;检测限为0.74ng。结论：本法简便、准确,重现性好,可作为检测祛风止痛胶囊中没食子酸含量的质控方法。     

RP-HPLC测定痛经宁胶囊中芍药苷的含量

目的建立痛经宁胶囊中芍药苷的HPLC含量测定方法。方法采用HypersilC18柱（250mm×4.6mm,5μm）,以乙腈-0.1%磷酸（15：85）为流动相;检测波长230nm;流速：1.0mL·min-1,柱温：30℃。结果芍药苷在0.256～1.536μg内线性关系良好,r=0.9999,平均回收率为99.49%,RSD=0.56%（n=9）。结论该方法简便、准确、重复性好、可作为痛经宁胶囊的含量测定方法。     

UPLC法测定止嗽化痰胶囊中吗啡、可待因和罂粟碱的含量

目的：建立止嗽化痰胶囊中吗啡、可待因和罂粟碱含量的UPLC测定方法。方法：采用ACQUITY UPLC? HSS C18柱（2.1mm×100mm,1.8μm）,以乙腈（A）-0.2%三氟乙酸（B）梯度洗脱;流量为0.4mL?min-1,柱温35℃,检测波长为237nm。结果：吗啡、可待因和罂粟碱的线性范围分别为0.005～0.131μg（r=0.999 4）、0.002～0.061μg（r=1.000）、 0.001～0.025（r=1.000）,平均回收率(n=6)分别为98.8%、95.2%、101.1%,其RSD分别为2.2%、 2.8%、3.3%。结论：本法可靠、准确,可用于该制剂的质量控制。     

高效液相色谱法测定感愈胶囊中绿原酸的含量

目的建立测定感愈胶囊中绿原酸含量。方法色谱柱为Kromasil C18柱（4.6 mm×250 mm,5μm）;流动相：乙腈-0.4%磷酸（10∶90）;流速1.0 ml.min-1;柱温：40℃;检测波长326 nm。结果绿原酸进样量在0.0414-0.828μg范围内线性关系良好（r=1.0000,n=7）,平均加样回收率为99.01%,RSD为1.40%（n=9）。结论该方法简便快速,结果准确,可用于感愈胶囊中绿原酸含量的测定。     

RP-HPLC法测定百乐眠胶囊中大黄素和大黄素甲醚的含量

目的建立RP-HPLC法测定百乐眠胶囊中大黄素和大黄素甲醚的含量。方法采用lichrospher C18色谱柱,流动相为甲醇：0.1%磷酸水溶液（82∶18）,流速为：1.0mL·min^-1,检测波长：254nm,柱温35℃。结果大黄素在0.0392～0.2741μg,r=0.9999,大黄素甲醚在0.0506～0.3544μg线性关系良好,r=0.9999。平均回收率大黄素为100.54%（RSD=2.18%）、大黄素甲醚为102.63%（RSD=1.63%）。结论本方法操作可靠、准确,适用于百乐眠胶囊中大黄素和大黄素甲醚的含量测定。     

HPLC法测定毛冬青胶囊中具栖冬青苷和毛冬青酸的含量

目的：建立HPLC法同时测定毛冬青胶囊中具栖冬青苷和毛冬青酸含量的方法,并对3个批次毛冬青胶囊中上述两种化合物进行定量分析。方法：Zorbax SB-C18（4.6 mm×150mm,5μm）色谱柱,流动相为甲醇-0.2%磷酸水溶液,梯度洗脱,检测波长215 nm,柱温40℃,流速1.0 mL·min-1,进样量20μL。结果：具栖冬青苷和毛冬青酸的线性范围分别为1.22-521.1μg·mL-1（r=0.9995）、1.23-289.6μg·mL-1（r=0.9991）,加样回收率分别为99.24%（RSD=0.68%）、99.53%（RSD=0.85%）。结论：该方法简便、准确、重复性好,可为毛冬青胶囊提供质量控制依据。     

HPLC法测定脊痛宁胶囊中松脂醇二葡萄糖苷的含量

目的：建立脊痛宁胶囊中松脂醇二葡萄糖苷的含量测定方法。方法：采用HPLC法,色谱柱为Agilent XDB-C18柱（150 mm×4.6 mm,5μm）,流动相为甲醇-水（20∶80）,流速：1.0 mL.min-1,检测波长：227 nm,柱温：40℃,进样量：10μL。结果：松脂醇二葡萄糖苷在21.3-213μg·mL-1的线性范围内呈现良好的线性关系（r=0.999 7）,平均加样回收率为101.2%,RSD=0.99%（n=6）;松脂醇二葡萄糖苷与其他杂质峰分离良好;三个批次的脊痛宁胶囊中松脂醇二葡萄糖苷的平均含量约为每粒（0.50±0.011 5）mg。结论：该方法用于检测脊痛宁胶囊中松脂醇二葡萄糖苷的含量,方便快捷,重现性好,可用于该药品的质量控制。     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Emerging drugs for epilepsy

Epilepsy affects ≤ 1% of the world's population. Antiepileptic drugs (AEDs) are the mainstay of treatment, although more than a third of patients are not rendered seizure free with existing medications. Uncontrolled epilepsy is associated with increased mortality and physical injuries, and a range of psychosocial morbidities, posing a substantial economic burden on individuals and society. Limitations of the present AEDs include suboptimal efficacy and their association with a host of adverse reactions. Continued efforts are being made in drug development to overcome these shortcomings employing a range of strategies, including modification of the structure of existing drugs, targeting novel molecular substrates and non-mechanism-based drug screening of compounds in traditional and newer animal models. This article reviews the need for new treatments and discusses some of the emerging compounds that have entered clinical development. The ultimate goal is to develop novel agents that can prevent the occurrence of seizures and the progression of epilepsy in at risk individuals.     

盐酸达泊西汀中甲磺酸甲酯、甲磺酸乙酯及甲磺酸异丙酯的顶空毛细管GC-ECD法测定

建立了衍生化顶空毛细管气相色谱-电子捕获检测器(ECD)法测定盐酸达泊西汀中的甲磺酸甲酯(MMS)、甲磺酸乙酯(EMS)和甲磺酸异丙酯(IMS).应用碘化钠衍生技术,使用PW-5毛细管柱,载气为氮气,ECD检测,程序升温.MMS、EMS和IMS分别在0.03～0.30、0.05～0.50和0.05～0.50 μg/ml浓度范围内线性关系良好,平均回收率分别为63.5％、100.3％和96.2％,最低检测限分别为0.30、0.50和0.50 ng/ml.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.